Get started
Author

Gabrielle A. Reckard

Observed name: G.A. Reckard
ORCID: 0000-0002-3939-230X
Observed ORCID: 0000-0002-3939-230X
OpenAlex ID: A5094282907
Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers
2024 · Grace C. Russell, Yassin Hamzaoui, et al. · Cytotherapy · 15
Manufacturing Process Improvement for Scale up of an Autologous Adoptive T Cell Product
2024 · D.S. Missan, G.A. Reckard, et al. · Cytotherapy · 1
Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma
2026 · Erin W. Meermeier, Dara S. Missan, et al. · Cancer Research Communications
Process Optimization: Standardizing Flow Cytometry Release Testing for Antigen-Activated T Cells with Preformulated Antibody Panel Technology
2025 · G.A. Reckard, D.S. Missan, et al. · Cytotherapy
Manual vs Automated Platelet Wash for T Cell Therapy Manufacturing Using An Automated Cell Processor.
2025 · D.S. Missan, G.A. Reckard, et al. · Cytotherapy
VALIDATION OF A FLOW CYTOMETRY RELEASE ASSAY UTILIZING INSTITUTIONAL CLINICAL ASSAY FOR COMPARISON FOR TCRαß+/CD19+ DEPLETED HAPLOIDENTICAL HEMATOPOIETIC PROGENITOR CELL GRAFTS
2024 · G.A. Reckard, D.S. Missan, et al. · Cytotherapy
Works count: 6
Citation count: 15
H-index: 1
I10-index: 1
Year
Topic
Type